BioCryst Pharmaceuticals has received funds worth $350 million that will be used in part to support the global launch of Orladeyo (berotralstat), an oral therapy to prevent hereditary angioedema (HAE) swelling attacks. The money came through various transactions with Royalty Pharma, a global buyer of pharmaceutical royalties, and…
Finger-prick blood samples taken at home could help to provide a simple and convenient way to predict acute hereditary angioedema (HAE) attacks, preliminary results from the Hereditary Angioedema Kininogen Assay (HAEKA) study in Germany suggest. Samples collected during attacks over the study’s course are expected to lead to the discovery…
One in three patients with hereditary angioedema (HAE) may have an impaired sense of smell, but this does not appear to be tied to changes in the genes responsible for odor detection, a small study found. The scientists said more research is needed, in larger patient populations, to better…
Get regular updates to your inbox.